Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02317380 · ClinicalTrials.gov registry record
Self-Affirmation and Defensiveness to Health Messages for the Self vs. a Close Other
A clinical trial of Cancer Prevention and Ego, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 1,019
- Enrollment target
- 1
- Study location
NCT02317380: Completed study of Cancer Prevention and Ego, sponsored by National Cancer Institute (NCI).
NCT02317380 is a study of Cancer Prevention and Ego that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 1,019 participants, above the 253-participant average among 6 other Cancer Prevention trials with a reported enrollment target (303% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02317380, a study of Cancer Prevention and Ego, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 1,019 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Researchers want to learn about people s beliefs and values. They also want to learn about how people respond to information about cancer risk. They have created two short studies. They have combined these studies for convenience. Objective: \- To learn about people s beliefs and values, and about how people respond to information about cancer risk. Eligibility: \- Adults age 40-70 who are overweight, have never had cancer, and have an opposite-sex close relationship with someone in that age group who is also overweight. Design: * This study will take place online or in a laboratory. * Participants will take part in two studies. One is Values Study. The other is Cancer Risk Information. * In Values Study, some participants will choose the most important value from a list. They will write about why that value is important to them. Others will choose the least important value from a list. They will write about why that value may be important to someone else. * In Cancer Risk Information, participants will read a health message about a cancer risk relevant to themselves or to a close other. Some will wear special glasses that track their eye movements as they read. * Participants will then answer questions about their beliefs about cancer risk and their intentions to lose weight. * Both studies will take 30 minutes.
Conditions Studied
Study Locations (1)
Maryland
- National Cancer Institute (NCI), 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,019 participants |
| Start Date | 2014-12-13 |
| Est. Completion | 2018-09-18 |
What the finished NCT02317380 record still lists
NCT02317380 is an observational study that tracks outcomes without assigning an intervention. Its 1,019 participants enrollment target places it among the larger protocols in the corpus, above the 253-participant average among 6 other Cancer Prevention trials with a reported enrollment target (303% higher).
The record links to 3 conditions, with Cancer Prevention appearing as the primary indexed condition, and to 0 interventions.
NCT02317380 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02317380 about?
NCT02317380 is a clinical study titled "Self-Affirmation and Defensiveness to Health Messages for the Self vs. a Close Other". Background: \- Researchers want to learn about people s beliefs and values. They also want to learn about how people respond to information about cancer risk. They have created two short studies. They have combined these studies for convenience. Objective: \- To learn about people s beliefs and v...
What is the current status of trial NCT02317380?
This trial is currently completed. The enrollment target is 1,019 participants. The study started on 2014-12-13. Estimated completion is 2018-09-18.
What conditions does trial NCT02317380 study?
This clinical trial studies the following conditions: Cancer Prevention, Ego, Social Science.
Who is sponsoring clinical trial NCT02317380?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02317380 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer Prevention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Implementation and Evaluation of an Evidence-Based, Multilevel Lifestyle Intervention for Underserved and Rural Populations in South Texas
RECRUITING · NA
-
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
RECRUITING · NA
-
Dietary Fiber and Time Restricted Eating
RECRUITING · NA
-
The Food Environment, Microbial Cysteine Metabolism, and Cancer Disparities
RECRUITING · NA
-
Eatwell Clinical Trial (R01)
RECRUITING · NA
-
Using Social Networks to Promote Physical Activity in African American and Hispanic Women
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
- NCT05225428 · 1,020 participants · NA
Video Education With Result Dependent dIsclosure
- NCT06697600 · 1,020 participants · NA
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- NCT06760637 · 1,020 participants · Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI